Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

Schering-Plough announces European filing of Sycrest (asenapine) for schizophrenia and bipolar I disorder

Schering-Plough Corporation has announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for Sycrest (asenapine) sublingual tablets for the treatment of schizophrenia and manic episodes associated with bipolar I disorder. The application will follow the Centralized Procedure.

2 Jun 2009

Discovery of proteins underlying devastating brain diseases

Scientists at the Wellcome Trust Sanger Institute have discovered a set of brain proteins responsible for some of the most common and devastating brain diseases.

19 May 2009

Cognition already seriously impaired in first episode of schizophrenia

Significant and widespread cognitive problems appear to exist in schizophrenia in its earliest phase, making it very hard for people with the disorder to work, study or be social, according to a new study published by the American Psychological Association.

13 May 2009

Inherited impulsivity predicts alcoholism

Solving the age-old chicken and the egg dilemma, Indiana University-Purdue University Indianapolis researchers report that genetic predisposition to impulsivity is a trait predictive of alcoholism. The study appears on the July print issue of the journal Alcoholism: Clinical and Experimental Research, available online on April 22.

23 Apr 2009

Genetic predisposition to impulsivity is a trait predictive of alcoholism

Solving the age-old chicken and the egg dilemma, Indiana University-Purdue University Indianapolis researchers report that genetic predisposition to impulsivity is a trait predictive of alcoholism.

22 Apr 2009

Genes influence impulsivity, which may then contribute to risk for developing alcoholism

Numerous studies have shown that highly impulsive behavior - defined as the tendency to choose small, immediate rewards over larger, delayed rewards - is more prevalent in drug addicts and alcoholics compared to individuals without addictions.

22 Apr 2009

Scientists suggest a mechanism for how lithium works in bipolar treatment

Lithium has been established for more than 50 years as one of the most effective treatments for bipolar mood disorder.

22 Apr 2009

Valproate exposure during pregnancy can impair a child's cognitive development

Three-year-olds whose mothers took the antiepileptic drug valproate during pregnancy had average IQs six to nine points lower than children exposed to three other antiepileptic drugs, a landmark multi-center study has found.

15 Apr 2009

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

Most psychiatrists who wrote clinical guidelines had financial ties to drug companies, study shows

Most of the psychiatrists on the American Psychiatric Association panels who wrote the newest clinical guidelines for how to treat depression, bipolar disorder and schizophrenia had financial ties to drug companies, according to a study by Boston researchers scheduled to be published this month in the journal Psychotherapy and Psychosomatics, the Boston Globe reports.

5 Apr 2009

District Court decision received in Concerta patent sase

The U.S. District Court for the District of Delaware has rendered a decision in the patent litigation between Alza Corporation, McNeil-PPC, Inc. and Andrx Pharmaceuticals LLC. McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which markets Concerta (methylphenidate HCI) Extended-Release Tablets CII, said the court held that the patent in suit is not valid or infringed by the filing of Andrx's Abbreviated New Drug Application.

1 Apr 2009

Repligen licenses uridine patent rights for treatment of bipolar disorder

Repligen Corporation has announced that it has exclusively licensed worldwide rights for the use of uridine in the treatment of patients with bipolar disorder from McLean Hospital.

31 Mar 2009

Eating disorders should be recognized as serious mental illnesses

In the U.S. and abroad, the failure of insurers and other gatekeepers to treatment to consistently recognize eating disorders as serious mental illnesses has resulted in an ongoing heath care crisis for sufferers and their families.

29 Mar 2009

Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments

Antipsychotic drugs, such as olanzapine (Zyprexa), risperidone (Risperdal) and quetiapine (Seroquel), are commonly used to treat psychotic disorders like schizophrenia, but also bipolar disorder and even behavioral problems related to dementia.

29 Mar 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009

Schizophrenia gene found to control the birth of new neurons

A gene that is arguably the most studied "schizophrenia gene" plays an unanticipated role in the brain: It controls the birth of new neurons in addition to their integration into existing brain circuitry, according to a report in the March 20th issue of the journal Cell, a Cell Press publication.

20 Mar 2009